CeftobiprolCeftobiprole%D8%B3%D9%81%D8%AA%D9%88%D8%A8%DB%8C%D9%BE%D8%B1%D9%88%D9%84CeftobiprolCeftobiproleCeftobiprol%D0%A6%D0%B5%D1%84%D1%82%D0%BE%D0%B1%D0%B8%D0%BF%D1%80%D0%BE%D0%BBCeftobiprolCeftobiprol%D0%A6%D0%B5%D1%84%D1%82%D0%BE%D0%B1%D1%96%D0%BF%D1%80%D0%BE%D0%BBCeftobiproleQ5057301%E5%A4%B4%E5%AD%A2%E6%AF%94%E6%99%AE
about
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus BacteremiaCeftobiprole in the Treatment of Pediatric Patients With PneumoniaOpen and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF DeviceCeftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaCeftobiprole in Hospital Acquired Pneumonia (2005-04-30)Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections (2005-09-30)Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI
P4844
Ceftobiprole for the treatment of pneumonia: a European perspectivePharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.Cross-reactivity in β-Lactam Allergy.Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections.Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trialsEvaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI
P921
Q61980005-3368BFBD-96AA-4586-9E30-2FD308C50194Q63401347-DCD06C73-F407-4FE3-9AE5-84C273656FE2Q63535241-F183977E-4FA2-4D9C-A115-2A88E32CC541Q63573386-7050981F-9014-4FB3-9EEA-C0DD71BBDE2CQ86247729-D37B2A2D-BB48-4FF0-8EA4-AC01A3B98DFFQ86247825-6DED6F67-5A47-403C-98DF-ACCE1A1845EDQ96179141-0C4D1C39-0153-4E7F-81FF-C1475B27D008
P4844
Q26796463-449F5DD8-FDA0-4881-940C-FF6F44287A48Q39164183-FFD5DA64-AF7F-4553-854D-CFA2EB696C9AQ39566665-F71A9B41-DA89-47B2-81F6-47A1AB96E607Q40963141-09ED34F5-1B77-42B2-A357-D08E3FB084FBQ41987583-2F66CEA3-087A-42B2-952B-BE4CE1EA6FE7Q49917379-2BD655EE-6DAC-44E9-9FF1-22B94241538FQ50208091-B14B43F0-28A7-4E16-8977-C4976375AEE2Q50208091-D6B8B5EC-A5B7-44B8-B67D-4386BB7F55D6Q64099242-B3DADB5E-23C1-4852-A03C-5449AEB3148DQ96179141-CBB62A70-14C7-42F6-AAD5-F7585ACBBADA
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ceftobiprol
@de
Ceftobiprol
@pl
Ceftobiprol
@ro
Ceftobiprol
@sh
Ceftobiprol
@sr
Ceftobiprole
@en
Ceftobiprole
@nl
Ceftobiprole
@pt
Ceftobiprole
@vi
Цефтобипрол
@ru
type
label
Ceftobiprol
@de
Ceftobiprol
@pl
Ceftobiprol
@ro
Ceftobiprol
@sh
Ceftobiprol
@sr
Ceftobiprole
@en
Ceftobiprole
@nl
Ceftobiprole
@pt
Ceftobiprole
@vi
Цефтобипрол
@ru
prefLabel
Ceftobiprol
@de
Ceftobiprol
@pl
Ceftobiprol
@ro
Ceftobiprol
@sh
Ceftobiprol
@sr
Ceftobiprole
@en
Ceftobiprole
@nl
Ceftobiprole
@pt
Ceftobiprole
@vi
Цефтобипрол
@ru
P486
P592
P6366
P646
P661
P662
P665
P683
P2017
C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[ ...... /C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
P231
209467-52-7
P232
P233
C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O
P234
1S/C20H22N8O6S2/c21-20-24-14(2 ...... 8-5+,25-11-/t10-,12-,18-/m1/s1
P235
VOAZJEPQLGBXGO-SDAWRPRTSA-N
P2566
100.129.666
P274
C₂₀H₂₂N₈O₆S₂
P2868
P3117
DTXSID40870229